{"id":11748,"date":"2021-02-11T17:23:49","date_gmt":"2021-02-11T11:53:49","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11748"},"modified":"2021-07-24T12:58:16","modified_gmt":"2021-07-24T07:28:16","slug":"recent-pharma-happenings-for-verily-janssen-avrobio","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio","title":{"rendered":"Verily &#8211; Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate;  Gut microbiome responsible for Multiple Sclerosis"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69ff1e3c05446\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69ff1e3c05446\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio\/#Verily_collaborates_with_Janssen_to_launch_COVID-19_immune_response_study\" >Verily collaborates with Janssen to launch COVID-19 immune response study<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio\/#Enhancing_the_response_to_immuno-oncology_in_pancreatic_cancer\" >Enhancing the response to immuno-oncology in pancreatic cancer&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio\/#Avrobio_gene_therapy_eradicates_toxic_substrate_in_Fabry_patient\" >Avrobio gene therapy eradicates toxic substrate in Fabry patient<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio\/#Multiple_Sclerosis_study_holds_the_gut_microbiome_for_the_disorder_source\" >Multiple Sclerosis study holds the gut microbiome for the disorder source&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Verily_collaborates_with_Janssen_to_launch_COVID-19_immune_response_study\"><\/span><strong>Verily collaborates with Janssen to launch COVID-19 immune response study<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Verily is partnering with Johnson &amp; Johnson\u2019s Janssen division to witness the body\u2019s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes.\u00a0<\/p>\n\n\n\n<p>The study will be launched by Verily\u2019s Project Baseline testing program and intends to collect biological information and real-world data in the weeks soon after a person tests positive for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-therapeutic-pipeline-vaccines\">COVID-19<\/a><\/strong>.<\/p>\n\n\n\n<p>The aim is to recognize early warning biomarkers, which could help guide healthcare providers through future treatments and potentially predict whether an individual\u2019s case may turn severe or not.<\/p>\n\n\n\n<p>Verily, Google\u2019s life-science-focused sibling company and Janssen will also seek to tap into the data generated by people during their everyday lives to seek for any previous health-related signals in the two years leading up to the point they consented to participate in the study as well as in the two years after.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Enhancing_the_response_to_immuno-oncology_in_pancreatic_cancer\"><\/span><strong>Enhancing the response to immuno-oncology in pancreatic cancer&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Immune-stimulating antibodies, which target the receptor CD40, are emerging as promising <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-market\">therapies for pancreatic cancer<\/a><\/strong>. However, they have only shrunk tumors in about half of patients who took them, along with chemotherapy, in the clinical trials.<\/p>\n\n\n\n<p>Researchers from the University of Pennsylvania\u2019s Abramson Cancer Center contemplate they have discovered one key to the lack of response, and it may be targetable with different drug combinations, as per their announcement.<\/p>\n\n\n\n<p>The scientists analyzed samples from patients with the most common pancreatic cancer, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-ductal-adenocarcinoma-pipeline-insight\">pancreatic ductal adenocarcinoma (PDAC)<\/a><\/strong>. They found that those with raised systemic inflammation levels in their blood before they were treated with a CD40 agonist and the chemo drug gemcitabine had appalling survival results. They reported their observations in the journal JCI Insight.<\/p>\n\n\n\n<p>The Penn team examined blood samples from 22 PDAC patients before and after being treated with the chemo-immunotherapy combination. Before they were treated, some patients had high inflammation levels, visible from markers as neutrophils and inflammatory cytokines like IL-6 and IL-8. Median overall survival in those patients was 5.8 months, whereas patients without inflammation before treatment survived on average 12.3 months.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Avrobio_gene_therapy_eradicates_toxic_substrate_in_Fabry_patient\"><\/span><strong>Avrobio gene therapy eradicates toxic substrate in Fabry patient<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The first<strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-epidemiology-forecast\">Fabry disease patient<\/a><\/strong> treated with Avrobio\u2019s Plato gene therapy platform in a phase 2 trial has undergone the complete clearance of toxic kidney substrate.&nbsp;<\/p>\n\n\n\n<p>Avrobio designed the Plato platform to optimize vector copy numbers, personalize the conditioning regimen, aid automated manufacturing and otherwise promote and industrialize its lentiviral vector-based approach to treating genetic diseases. Late in 2019, a Fabry patient in phase 2 clinical trial of ex vivo lentiviral gene therapy AVR-RD-01 became the first patient dosed using Plato.&nbsp;<\/p>\n\n\n\n<p>Avrobio shared details of the efficacy of Plato after having tracked the patient for 12 months. The patient experienced a 100% reduction in Gb3 inclusions at 12 months. At baseline, the patient averaged four Gb3 inclusions per peritubular capillary. One year later, the figure had decreased to zero. The results were generated by two blinded pathologists who independently evaluated 99 kidney biopsy images.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Multiple_Sclerosis_study_holds_the_gut_microbiome_for_the_disorder_source\"><\/span><strong>Multiple Sclerosis study holds the gut microbiome for the disorder source&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A new study showed that the inflammatory molecules found in the brain are not responsible for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\">Multiple Sclerosis<\/a><\/strong>.&nbsp;<\/p>\n\n\n\n<p>Two types of interleukin-17 (IL-17) molecules generated explicitly in the gut regulate its microbiome and seem to be critical drivers of Multiple Sclerosis, a research team led by the Johannes Gutenberg-University Mainz in Germany has reported.<\/p>\n\n\n\n<p>The observations published in Science Immunology could inform the development of therapies that target IL-17 signaling for chronic inflammatory diseases as per the researchers.<\/p>\n\n\n\n<p>CD4+ T helper cells that produce IL-17A and IL-17F (TH17 cells) are indicated in the Multiple Sclerosis development. However, scientists have long debated whether the T cells, specifically their inflammatory functions in the CNS, or the two cytokines driving the disease.<\/p>\n\n\n\n<p>A widely used mouse model of Multiple Sclerosis uses the myelin sheath around nerve cells to stimulate CNS inflammation similar to that seen in <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-epidemiology-forecast\">Multiple Sclerosis patients<\/a><\/strong>&#8216; brain and spinal cord. For the study, the researchers immunized mice lacking the expression of IL-17A and IL-17F with the myelin pieces and found that many animals did not develop Multiple Sclerosis symptoms. Moreover, those that did become ill showed relatively mild disease, from which they recovered quickly.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Verily collaborates with Janssen to launch COVID-19 immune response study Verily is partnering with Johnson &amp; Johnson\u2019s Janssen division to witness the body\u2019s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes.\u00a0 The study will be launched by Verily\u2019s Project Baseline testing program and intends to collect [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":11751,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[16689,420,639],"industry":[17225],"therapeutic_areas":[17240,17239,17233,17227,17228],"class_list":["post-11748","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-healthcare-news","tag-news","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-gastroenterology","therapeutic_areas-hematological-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Verily-Janssen deal; Pancreatic cancer research; Avrobio&#039;s gene therapy<\/title>\n<meta name=\"description\" content=\"Enhancing the response in pancreatic cancer; Gut microbiome responsible for Multiple Sclerosis; Avrobio gene therapy eradicates toxic subt..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verily-Janssen deal; Pancreatic cancer research; Avrobio&#039;s gene therapy\" \/>\n<meta property=\"og:description\" content=\"Enhancing the response in pancreatic cancer; Gut microbiome responsible for Multiple Sclerosis; Avrobio gene therapy eradicates toxic subt..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-11T11:53:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/11172051\/recent-pharma-biotech-news-updates-for-verily-janssen-avrobio.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Verily-Janssen deal; Pancreatic cancer research; Avrobio's gene therapy","description":"Enhancing the response in pancreatic cancer; Gut microbiome responsible for Multiple Sclerosis; Avrobio gene therapy eradicates toxic subt..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio","og_locale":"en_US","og_type":"article","og_title":"Verily-Janssen deal; Pancreatic cancer research; Avrobio's gene therapy","og_description":"Enhancing the response in pancreatic cancer; Gut microbiome responsible for Multiple Sclerosis; Avrobio gene therapy eradicates toxic subt..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-02-11T11:53:49+00:00","article_modified_time":"2021-07-24T07:28:16+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/11172051\/recent-pharma-biotech-news-updates-for-verily-janssen-avrobio.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio","name":"Verily-Janssen deal; Pancreatic cancer research; Avrobio's gene therapy","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/11172051\/recent-pharma-biotech-news-updates-for-verily-janssen-avrobio.jpg","datePublished":"2021-02-11T11:53:49+00:00","dateModified":"2021-07-24T07:28:16+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Enhancing the response in pancreatic cancer; Gut microbiome responsible for Multiple Sclerosis; Avrobio gene therapy eradicates toxic subt..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-verily-janssen-avrobio#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/11172051\/recent-pharma-biotech-news-updates-for-verily-janssen-avrobio.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/11172051\/recent-pharma-biotech-news-updates-for-verily-janssen-avrobio.jpg","width":772,"height":482,"caption":"recent-pharma-biotech-news-updates-for-verily-janssen-avrobio"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/11172051\/recent-pharma-biotech-news-updates-for-verily-janssen-avrobio-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Healthcare News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Healthcare News<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 11, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 11, 2021 5:23 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"recent-pharma-biotech-news-updates-for-verily-janssen-avrobio","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11748"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11748\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11751"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11748"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11748"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}